MA34952B1 - Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme - Google Patents
Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiformeInfo
- Publication number
- MA34952B1 MA34952B1 MA36217A MA36217A MA34952B1 MA 34952 B1 MA34952 B1 MA 34952B1 MA 36217 A MA36217 A MA 36217A MA 36217 A MA36217 A MA 36217A MA 34952 B1 MA34952 B1 MA 34952B1
- Authority
- MA
- Morocco
- Prior art keywords
- macitentan
- treatment
- combinations
- glioblastoma
- radiotherapy
- Prior art date
Links
- 208000005017 glioblastoma Diseases 0.000 title abstract 2
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001039 macitentan Drugs 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne l'utilisation de macitentan en combinaison avec un agent thérapeutique cytotoxique (tel que le témozolomide ou le paclitaxel), à une radiothérapie ou à la fois à un agent thérapeutique cytotoxique et à une radiothérapie, dans le traitement d'un gliome malin, en particulier un glioblastome multiforme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050494 | 2011-02-04 | ||
| PCT/IB2012/050513 WO2012104822A1 (fr) | 2011-02-04 | 2012-02-03 | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34952B1 true MA34952B1 (fr) | 2014-03-01 |
Family
ID=45787254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36217A MA34952B1 (fr) | 2011-02-04 | 2012-02-03 | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130310407A1 (fr) |
| EP (2) | EP2670405B1 (fr) |
| JP (2) | JP5642892B2 (fr) |
| KR (1) | KR101563069B1 (fr) |
| CN (1) | CN103327975A (fr) |
| AR (1) | AR085132A1 (fr) |
| AU (1) | AU2012213036A1 (fr) |
| BR (1) | BR112013019680A2 (fr) |
| CA (1) | CA2823994A1 (fr) |
| CL (1) | CL2013002193A1 (fr) |
| CO (1) | CO6761366A2 (fr) |
| EA (1) | EA201391131A1 (fr) |
| IL (1) | IL227747A0 (fr) |
| MA (1) | MA34952B1 (fr) |
| MX (1) | MX2013008798A (fr) |
| PH (1) | PH12013501461A1 (fr) |
| SG (1) | SG192600A1 (fr) |
| TN (1) | TN2013000333A1 (fr) |
| TW (1) | TW201309298A (fr) |
| WO (1) | WO2012104822A1 (fr) |
| ZA (1) | ZA201306613B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ567188A (en) | 2005-09-12 | 2011-04-29 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| TWI483938B (zh) | 2009-08-10 | 2015-05-11 | Univ Texas | 以內皮素受體抑制劑處理星狀腫瘤細胞 |
| CN103397308A (zh) * | 2013-08-01 | 2013-11-20 | 光垒光电科技（上海）有限公司 | 用于mocvd设备的喷淋头 |
| TWI559928B (en) * | 2014-08-20 | 2016-12-01 | Academia Sinica | Methods for enhancing permeability to blood-brain barrier and uses thereof |
| KR101701619B1 (ko) | 2015-06-26 | 2017-02-01 | 건양대학교산학협력단 | 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물 |
| KR102574253B1 (ko) | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 |
| CN115317604B (zh) * | 2022-08-11 | 2023-09-22 | 南京脑科医院 | 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100432070C (zh) * | 2000-12-18 | 2008-11-12 | 埃科特莱茵药品有限公司 | 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用 |
| NZ567188A (en) | 2005-09-12 | 2011-04-29 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| WO2008111092A1 (fr) * | 2007-03-09 | 2008-09-18 | Fresenius Kabi Oncology Limited | Forme cristalline de monohydrate de témozolomide et procédé de préparation de cette dernière |
| RU2494736C2 (ru) | 2008-02-20 | 2013-10-10 | Актелион Фармасьютиклз Лтд | Комбинация, включающая паклитаксел, для лечения рака яичников |
| TWI483938B (zh) * | 2009-08-10 | 2015-05-11 | Univ Texas | 以內皮素受體抑制劑處理星狀腫瘤細胞 |
-
2012
- 2012-02-03 EP EP12706925.0A patent/EP2670405B1/fr not_active Not-in-force
- 2012-02-03 CA CA2823994A patent/CA2823994A1/fr not_active Abandoned
- 2012-02-03 CN CN2012800059659A patent/CN103327975A/zh active Pending
- 2012-02-03 MX MX2013008798A patent/MX2013008798A/es active IP Right Grant
- 2012-02-03 WO PCT/IB2012/050513 patent/WO2012104822A1/fr not_active Ceased
- 2012-02-03 KR KR1020137023170A patent/KR101563069B1/ko not_active Expired - Fee Related
- 2012-02-03 BR BR112013019680A patent/BR112013019680A2/pt not_active IP Right Cessation
- 2012-02-03 AR ARP120100357A patent/AR085132A1/es unknown
- 2012-02-03 EA EA201391131A patent/EA201391131A1/ru unknown
- 2012-02-03 AU AU2012213036A patent/AU2012213036A1/en not_active Abandoned
- 2012-02-03 PH PH1/2013/501461A patent/PH12013501461A1/en unknown
- 2012-02-03 US US13/983,383 patent/US20130310407A1/en not_active Abandoned
- 2012-02-03 EP EP15178064.0A patent/EP2965757A1/fr not_active Withdrawn
- 2012-02-03 SG SG2013058979A patent/SG192600A1/en unknown
- 2012-02-03 TW TW101103560A patent/TW201309298A/zh unknown
- 2012-02-03 JP JP2013552318A patent/JP5642892B2/ja not_active Expired - Fee Related
- 2012-02-03 MA MA36217A patent/MA34952B1/fr unknown
-
2013
- 2013-07-10 CO CO13163973A patent/CO6761366A2/es not_active Application Discontinuation
- 2013-07-31 CL CL2013002193A patent/CL2013002193A1/es unknown
- 2013-08-01 IL IL227747A patent/IL227747A0/en unknown
- 2013-08-01 TN TNP2013000333A patent/TN2013000333A1/fr unknown
- 2013-09-03 ZA ZA2013/06613A patent/ZA201306613B/en unknown
-
2014
- 2014-10-28 JP JP2014219218A patent/JP2015057409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014504636A (ja) | 2014-02-24 |
| WO2012104822A1 (fr) | 2012-08-09 |
| TN2013000333A1 (en) | 2015-01-20 |
| CN103327975A (zh) | 2013-09-25 |
| CO6761366A2 (es) | 2013-09-30 |
| AU2012213036A1 (en) | 2013-09-19 |
| JP2015057409A (ja) | 2015-03-26 |
| CL2013002193A1 (es) | 2014-05-09 |
| KR101563069B1 (ko) | 2015-10-23 |
| SG192600A1 (en) | 2013-09-30 |
| EA201391131A1 (ru) | 2013-12-30 |
| US20130310407A1 (en) | 2013-11-21 |
| IL227747A0 (en) | 2013-09-30 |
| TW201309298A (zh) | 2013-03-01 |
| CA2823994A1 (fr) | 2012-08-09 |
| EP2965757A1 (fr) | 2016-01-13 |
| BR112013019680A2 (pt) | 2016-10-11 |
| NZ615005A (en) | 2015-10-30 |
| AR085132A1 (es) | 2013-09-11 |
| PH12013501461A1 (en) | 2019-03-22 |
| EP2670405A1 (fr) | 2013-12-11 |
| ZA201306613B (en) | 2015-04-29 |
| MX2013008798A (es) | 2013-10-17 |
| KR20130118981A (ko) | 2013-10-30 |
| JP5642892B2 (ja) | 2014-12-17 |
| EP2670405B1 (fr) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
| MA35210B1 (fr) | Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer | |
| EP2868667A4 (fr) | Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer | |
| MA39094A1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| CL2008001374A1 (es) | Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. | |
| UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
| MX391101B (es) | Complejo de agentes quimioterapéuticos en microburbujas para terapia sonodinámica. | |
| MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
| EP2154971A4 (fr) | Combinaison pharmaceutique synergique pour le traitement du cancer | |
| GB201204263D0 (en) | Giloma treatment | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| EP2889032A4 (fr) | Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| EP2671524A4 (fr) | Cathéter pour le traitement d'une grossesse extra-utérine, guide de cathéter et unité de cathéter pour le traitement d'une grossesse extra-utérine | |
| MA39146A1 (fr) | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma | |
| EP2208498A4 (fr) | Composition pharmaceutique comprenant une combinaison de divers agents veinotoniques et vasoprotecteurs pour le traitement de l'insuffisance veineuse chronique | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| MA35281B1 (fr) | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques | |
| MA34827B1 (fr) | Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes | |
| MA44700A (fr) | Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer | |
| AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
| MA34106B1 (fr) | Combinaison de composés organiques | |
| EA201071412A1 (ru) | Дронедарон для предотвращения кардиоверсии |